Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FREY......CHPT.......BLNK......MULN.......https://stockcharts.com/h-sc/ui?s=FREY&p=W&yr=1&mn=3&dy=0&id=p96837884856
,,,,,,,,,,
$MULN
— TGS Trades (@TGS_Trades) May 4, 2024
05.04.24 Saturday update for #MULN:
- Up 32% net over past 5 trading days. $3.16 to $4.16.
- Approved for $45K HVIP rebate in CA for Mullen 3 trucks, plus $7.5K federal rebate.
- Adds large commercial electric dealer to network (Pritchard Electric)
- Short interest… pic.twitter.com/i0XjVBXMIu
$CBDW Embracing a New Era in Investor Communications
Commenting on the launch, Greg Lambrecht, CEO of 1606 Corp., expressed unwavering enthusiasm about the potential of IR Chat to transform investor relations. “Our Chat IR solution heralds a new era in investor communications, offering a dynamic and interactive platform for public companies to engage with their shareholders and potential investors effectively,” said Lambrecht. “We believe this innovative technology will drive greater transparency, trust, and engagement within the investor community.” https://cbdw.ai/news/1606-corp-unveils-new-ai-vertical-ir-chat-a-bot-for-public-companies-and-investors/
ALYI getting run up right now .0017
$CBIA Leads Retail Revolution with Introduction of Innovative Customer Loyalty Program https://finance.yahoo.com/news/canopus-biopharma-inc-cbia-dba-120000564.html
JAGX it’s time hit the ask. .29
$EARI Large volume. New marketing campaign and recent acquisition of Reef cannabis infused drinks: https://otcmarkets.com/stock/EARI/news/EARI-Beverage-Group-OTC-EARI-Acquires-Exclusive-Licensing-Rights-for-Reef-Drinks?id=433037
$CBDW 1606's unique sales strategy
Our focus is not just on expanding our technology but also on securing strategic partnerships across industries. We aim to integrate our conversational AI solutions with major independent sales organizations (ISOs), enhancing our market reach and operational efficiency. This strategy positions CBDW as a crucial player in a market poised for significant growth, reflecting our commitment to our investors and partners alike. The Company has fielded significant interest already from independent sales organizations in the public sector as well public companies. Relationships have been established with ISO's allowing access to the tens of thousands of publicly-traded companies, providing what we believe is a massive opportunity.
https://www.newswire.com/news/1606-corp-unveils-new-ai-vertical-ir-chat-a-bot-for-public-companies-22315336
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to lurasidone - never previously shown with an oral antidepressant. Suicidality signal met the study's promising zone criteria and the akathisia signal approached statistical significance (P=0.076)
Both NRX-101 and lurasidone, an accepted standard of care in Bipolar Depression, demonstrated approximately 50% reduction in symptoms of depression
These data are comparable to previous statistically-significant finding of reduced suicidality and in the published STABIL-B trial and support an approval pathway via a 300-person registrational trial with sustained remission in suicidality as the primary endpoint
Company believes that an oral antidepressant that demonstrates reduction in suicidality has potential to become standard of care for treatment of bipolar depression.
Data from this study expand the potential utility of NRx-101 to treat both patients with suicidal bipolar depression (who will require prior use of ketamine) and those without subacute suicidality (nearly 7 million patients in the US).
RADNOR, Pa., April 30, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company today that its Breakthrough Therapy designated investigational drug NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency. Because of the high-risk nature of these patients, a placebo group could not be employed, and NRX-101, a fixed dose combination of D-cycloserine (DCS) and lurasidone, was compared to lurasidone alone (the standard of care). In the Company's previously published STABIL-B trial (STABIL-B), NRX-101 was demonstrated to be superior to lurasidone in reducing both depression and suicidality after ketamine while showing a trend towards reducing akathisia (a side effect involving restlessness and agitation that is considered a warning sign of impending suicide). In this trial, without prior use of ketamine, NRX-101 and lurasidone were comparable in their effect on depression. The trial was a randomized, prospective, double-blind study conducted at multiple sites in the Unites States whose protocol and statistical analysis plan may be viewed on www.clinicaltrials.gov (NCT03395392).
"We are gratified by these results, which extend the findings of the STABIL-B trial in suggesting that NRX-101 has the potential to be the first oral antidepressant to decrease potential for suicide, whereas all currently approved oral antidepressants are known to increase the risk of suicide," said Prof. Jonathan Javitt, MD, MPH, the Company's Chairman and Chief Scientist. "Should these findings be confirmed in a registrational trial of 300 patients, NRX-101 has the potential to represent a paradigm-changing blockbuster drug. The finding of a dramatic difference in akathisia was also seen in the STABIL-B trial and provides important mechanistic support for the difference seen on the Columbia Suicide Severity Rating Scale. Many of the patients who tragically die from suicide in bipolar depression are taking traditional antidepressants at the time of their death, a tragedy we have seen within the families of our investors and board members, as well as the many patients we have known. If today's findings are replicated in a registration-sized trial, we will change the world for patients who currently have a 50% lifetime risk of suicide attempt, a 20% lifetime risk of death by suicide, and whose only approved treatment option today is electroshock therapy."
"These findings are consistent with our original Phase 2 objectives and promising zone methodology in terms of a demonstrable advantage of NRX-101 compared to the standard of care in treating patients with bipolar depression who are known to be at high risk of suicide. We originally proposed to test suicidality, rather than depression as the primary endpoint for this trial and took the advice of senior FDA leadership that demonstrating a difference in suicidality might be too challenging. Today's findings demonstrate that differences in suicidality and akathisia can be demonstrated compared to best available antidepressant therapy in a properly sized registration trial and that superiority over placebo on the depression scale may readily be demonstrated in a less acute patient population where it would be safe to do so," said Dr. Philip Lavin, the study's Lead Methodologist. Dr. Lavin is one of the world's most widely published statisticians who has led the approval/clearance of more than 80 drugs, devices, and biologics.
In the current study, without prior use of ketamine, NRX-101 and lurasidone exhibited comparable antidepressant effects, each reducing depression (the primary endpoint) on the Montgomery Asberg Depression Rating Scale (MADRS) by about 50% from baseline. Lurasidone is known to reduce symptoms of depression by approximately 4 points in multiple registration trials compared to placebo.
Analysis of suicidality using the Columbia Suicide Severity Rating Scale (C-SSRS) demonstrated a sustained 33% advantage in remission from suicidality favoring NRX-101 (see figure). This difference was not statistically significant at the phase 2 sample size but met the study's original promising zone criteria and, if sustained in a registration trial of 300 or more patients, would be powered to yield a statistically significant result. The reduction in suicidality is comparable to that demonstrated after ketamine, both in the Company's STABIL-B trial and in an independently conducted trial comparing DCS to placebo after ketamine (Chen, et. al.). A meaningful remission in suicidality has not been demonstrated with any prior oral antidepressant drug – indeed, antidepressant drugs carry a Black Box warning of increased suicide risk.
Reduction in akathisia was first identified in the laboratory as a distinguishing feature of DCS and is the basis of the approved claims in the Company's Composition of Matter patents. Akathisia is often characterized as a state of agitation and motor restlessness that is associated with particularly impulsive and tragically effective attempts at suicide, such as hanging, shooting, jumping from buildings and in front of vehicles and trains. In this trial, a 75% relative difference was seen on the Barnes Akathisia Rating Scale (BARS), with two-sided P=0.076, which would be expected to achieve significance in a properly powered registration-sized trial. While reduction in akathisia is not proposed as a primary labeled indication, continued finding of a statistically significant reduction in this side effect would be highly supportive of a demonstrated primary endpoint of reduced suicidality and would provide clinical corroboration.
Based on these findings and widespread adoption of ketamine as initial treatment for suicidal depression, the Company believes that NRX-101 may become the drug of choice for potentiating the effect of ketamine in patients with acute and subacute suicidality. The FDA recently affirmed to the Company that the Special Protocol Agreement for this indication remains in place, subject to the Company filing a New Drug Approval for ketamine, which is expected by July 2024. Moreover the Company aims to explore the role of NRX-101 as primary treatment for the much larger population (approximately 7 million in the US) of patients with bipolar depression who do not have active suicidality and, therefore, do not require prior treatment with intravenous ketamine.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL01020&sd=2024-04-30 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-promising-findings-in-phase-2b3-clinical-trial-of-nrx-101-vs-lurasidone-for-treatment-of-suicidal-bipolar-depression-302131482.html
SOURCE NRx Pharmaceuticals
Guess who $IDGR hired as a Director?:
David Weintraub
David Weintraub is the former CEO of Swifty Car Wash, a company that he successfully took public and then returned to private holding. During his over 30 years of investment banking experience, Mr. Weintraub has personally raised hundreds of millions of dollars in capital, primarily for public companies.
David Weintraub is the President of Ideal Group's wholly owned subsidiary Portfolio Partners Inc. Portfolio Partners, Inc. is the parent company of Travel Zen, Inc., which acquires deeds to fractional timeshares in a portfolio of premium resorts concentrated during spring break at the most popular ski resorts in the USA
Z
#BreakingNews: $CBDW 1606 Corp. Unveils New AI Vertical: IR Chat, a Bot for Public Companies and Investors https://www.accesswire.com/857819/1606-corp-unveils-new-ai-vertical-ir-chat-a-bot-for-public-companies-and-investors
AGBA...............MULN........................https://stockcharts.com/h-sc/ui?s=AGBA&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
New Director of $IDGR Robert Egeland has done over 28,000 Mortgages.
He is the head of Oxygen Commercial, the newest subsidiary of $IDGR.
https://www.otcmarkets.com/stock/IDGR/news/Ideal-Group-of-Companies-Inc-Appoints-Robert-Egeland-as-Vice-Chairman-and-Begins-Trading-Under-New-Symbol-IDGR?id=429571
Z
$AGBA Majority shareholder support already obtained from both AGBA and Triller. Estimating 3-4 weeks now for merger combination to complete.
FREY......CHPT......BLNK........MULN..........................https://stockcharts.com/h-sc/ui?s=FREY&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=CHPT&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=BLNK&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
..........................https://www.mullenusa.com/battery
$CBDW 1606 Corp. CEO Greg Lambrecht in a recent interview with the team at Redchip mentioned multiple vertical expansion plans for 1606 Corps AI Chatbot.
cbdw.ai
redchip.com
AGBA..................MULN.........................https://chartexchange.com/symbol/nasdaq-muln/
https://chartexchange.com/symbol/nasdaq-AGBA/
$RONN reports the hydrogen market continues to grow and after several months of talks expects to sign a mou regarding a VERY significant capital equity infusion.
$RONN reports the hydrogen market continues to grow and after several months of talks expects to sign a mou regarding a VERY significant capital equity infusion.#Hydrogen #HFCEV #EV #HydrogenEnergy
— RONN inc (Formerly $LPHM) (@leepharma) April 26, 2024
GOEV..................MULN......................................https://stockcharts.com/h-sc/ui?s=GOEVV&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
$AGBA Triller going to see ‘biggest influx’ of users after new TikTok law!!!
https://www.foxbusiness.com/video/6351757905112
Triller CEO Bobby Sarnevesht reacts to recently signed TikTok legislation and shares why his product is a viable alternative!
GROY...................................https://stockcharts.com/h-sc/ui?s=GROY&p=D&yr=0&mn=2&dy=12&id=p84071410134
TPET...................MULN.................................https://stockcharts.com/h-sc/ui?s=TPET&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
IGPK..... HUGE MOVE.... check out >>>>>>> merge with a billion in Revs just about completed..
TheStockGuru
@Austria_9999
$IGPK : JFHE
Phase - 1 second part will be fill soon. EXPECTING otc 2023 annual and first quarter 2024 report will upload in disclosure, Attorney letter will updated, Business description and insiders name Changes and yield sign will remove Today end of the day or Tomorrow!!!!!
12:17 PM · Apr 23, 2024
876 Views
KULR...................MULN...................................https://stockcharts.com/h-sc/ui?s=KULR&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
$LBRG Expansion to Meet Rising E-Commerce Demand - Exploding Rev's here way undervalued pps!
https://finance.yahoo.com/news/enhanced-inventory-management-solutions-meet-120500771.html
Best Growth Stock's full report breaks through the noise and offers a comprehensive analysis of the $AGBA Group Holding Limited merger with Triller.
https://bestgrowthstocks.com/access-agba-analysis/
$PDGO is thrilled to announce the successful acquisition of a 100% interest in 58 oil and gas wells along with 600 acres of land in Oklahoma. https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
AKBA..........................MULN.......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
#NASDAQ: $PARA Analysis covers Paramount Global’s buyout options, potential outcomes, current estimated valuation, cash position, breakdown of recent developments, short interest, financial performance, and more.
CLICK HERE>>> https://nasdaq.com/press-release/bestgrowthstocks.com-unveils-in-depth-review-of-paramount-globals-latest-merger-bid
GOEV.................MULN.........................https://stockcharts.com/h-sc/ui?s=GOEV&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
SNAX......RZLT......................https://stockcharts.com/h-sc/ui?s=SNAX&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=RZLT&p=D&yr=0&mn=2&dy=12&id=p84071410134
News on $MNTS and $ASTI Partnership: Momentus and Ascent Solar Technologies Partner to Bring Leading-Edge Solar Arrays to Market
Innovative solar arrays to address burgeoning demand
SAN JOSE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies, (Nasdaq: ASTI) (“Ascent”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.
The rapid growth in the production and deployment of thousands of satellites in space has led to the burgeoning need for low-cost, reliable and high performing solar arrays. Momentus and Ascent are excited to partner to market a leading-edge solar array designed to provide key advantages to customers such as lower costs, resiliency with less degradation in the harsh environment in space, flexibility, and the ability to efficiently generate large amounts of power.
Building off the successes of the pathfinder demonstration of TASSA that was launched to Low-Earth Orbit on the Vigoride-6 mission one year ago and tested in space for several months, Momentus plans to add a high-power photovoltaic array as a differentiated feature of the next iteration of the TASSA product under development. Last year’s pathfinder TASSA demonstration validated solar blankets from Ascent, as a mass efficient and robust power generation solution. Momentus plans to incorporate in TASSA new higher efficiency solar blankets from Ascent composed of space industry optimized Titan Modules, achieving even lower cost per kW of power.
TASSA will continue to utilize Vigoride hardware with spaceflight heritage to provide customers an entire array subsystem, complete with solar array rotation actuators and controllers. This approach is oriented at streamlining mission schedules and minimizing clean room bottlenecks during spacecraft assembly integration and testing. TASSA is designed for responsive launch as well as more efficient flatpack configurations which allow for more satellites to fit within launch vehicle payload fairings.
“TASSA is designed to generate extensive power at very low cost while minimizing mass and volume,” said Rob Schwarz, Momentus CTO. “TASSA is intended to allow Smallsats to generate kilowatts of power on orbit without breaking their mass, thermal, or cost budgets. This design optimization also facilitates improved satellite packing efficiencies and allows constellations to be fielded quicker and cheaper.”
TASSA is also retractable and re-deployable providing a means for the minimization of cross-sectional area and array exposure if notified of potential conjunction or other orbital hazards such as space weather. This could enable TASSA to facilitate longer mission durations and increased assurance of spacecraft operations on orbit.
“Ascent’s flexible, lightweight photovoltaic modules are ideal for the space environment,” said Paul Warley, CEO of Ascent Solar Technologies. “Our CIGS products are resilient to radiation and other drivers of degradation while operating in orbits between the Earth and the Moon. For those designing space missions, this equates to more end-of-life power with an order of magnitude less mass. We’re excited to be the baseline power generation solution for TASSA, and look forward to continuing to collaborate with the Momentus team to provide long-lived and sustainable solutions for proliferated space architectures.”
ABOUT MOMENTUS
Momentus is a U.S. commercial space company that offers satellite buses and technologies, as well as space services including transportation, hosted payloads, and other in-orbit services.
ABOUT ASCENT SOLAR TECHNOLOGIES, INC.
Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in environments where mass, performance, reliability, and resilience matter. Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado. To learn more, visit https://www.ascentsolar.com or follow the Company on LinkedIn and X (formerly Twitter).
Forward-Looking Statements
This press release contains certain statements which may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Momentus or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. The words “may,” “will,” “anticipate,” “believe,” “expect,” “continue,” “could,” “estimate,” “future,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “aim,” “strive,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus’ control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: the ability of the Company to generate revenue and raise capital in order to continue as a going concern; the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its operations; the ability of the Company to effectively market and sell satellite transport services and planned in-orbit services; the ability of the Company to protect its intellectual property and trade secrets; the development of markets for satellite transport and in-orbit services; the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology; delays or impediments that the Company may face in the development, manufacture and deployment of next generation satellite transport systems; the ability of the Company to convert backlog or inbound inquiries into revenue; changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and business, including export control license requirements; the ability to attract or maintain a qualified workforce with the required security clearances and requisite skills; product service or product or launch failures or delays that could lead customers to use competitors’ services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the Company’s ability to comply with the terms of its National Security Agreement and any related compliance measures instituted by the director who was approved by the CFIUS Monitoring Agencies; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and/or other risks and uncertainties. These are only some of the factors that may affect the forward-looking statements contained in this press release. For a discussion identifying additional important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, see the company’s filings with the U.S. Securities and Exchange Commission including, but not limited to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The Company’s filings may be accessed through the Investor Relations page of its website, investors.momentus.space, or through the website maintained by the SEC at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
MEDIA CONTACT
Spencer Herrmann
FischTank PR
ascent@fischtankpr.com
INVESTOR RELATIONS CONTACT
ir@ascentsolar.com
https://www.globenewswire.com/newsroom/ti?nf=OTA5MDY1OSM2MjA0NDU2IzUwMDExNDU4Mw==
https://ml.globenewswire.com/media/NWI4MGQxZTUtZDM5My00M2QwLWEzNjAtYjFiM2Q2NTVkYmUzLTUwMDExNDU4Mw==/tiny/Ascent-Solar-Technologies-Inc-.png
Source: Ascent Solar Technologies, Inc.
$PDGO Ready to run any day now with this update!! https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
$RONN Big buying opportunity here >>> https://schrts.co/CfIJGxhZ
$RONN ON RADAR
⚡️ Revolutionizing transportation with $RONN hydrogen cars! 🚗💧 Experience the future of mobility with zero emissions and cutting-edge technology. Join us on the journey towards sustainable driving and a cleaner planet! 🌱🌐 #RONN #HydrogenCars #Sustainability
— DACE (@DACE0325) April 17, 2024
Trending $ABQQ…
$BIDCF ON NEWS WATCH -- BlockchainK2 Announces Update on Strategic Investment in RealBlocks https://finance.yahoo.com/news/blockchaink2-announces-strategic-investment-realblocks-070000511.html
$PDGO Announces Acquisition of 100% Interest in 58 Oil and Gas Wells and 600 Acres of Land
in Oklahoma https://www.otcmarkets.com/otcapi/company/dns/news/document/73893/content
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Formulation based on prior patents by NRx founder
Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration
Company expects Composition of Matter patent protection
Company previously executed joint development agreement with US manufacturer of insulin pumps
RADNOR, Pa., April 15, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100. This new formulation has the key advantage of achieving neutral pH, in contrast to the acidic pH of generic formulations of ketamine. Acidic substances are tolerated when diluted for intravenous use, but cause pain and may cause skin ulcers if administered subcutaneously. This patentable invention may enable the administration of ketamine in insulin pump-like devices in the clinic setting, eliminating the requirement for intravenous infusion personnel. NeuroRx, Inc. previously executed a joint development agreement with a manufacturer of insulin pumps but has been awaiting a suitable, pH neutral formulation of ketamine.
With this proprietary formulation, developed with our partner Nephron Pharmaceuticals, a leading sterile products manufacturer, NRx is expected to generate one or more patents, such as composition of matter or formulation.
HTX-100 is expected to be marketed by HOPE Therapeutics, Inc., a wholly owned subsidiary of NRx.
"The current formulation of IV Ketamine was developed for battlefield use in the 1960s and has remained relatively static since then. With our new formulation, and Nephron's state of the art manufacturing expertise, we are pleased to be approaching the market with an improved formulation ready for use in modern medicine," said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. "Development of a pH-neutral, subcutaneous form of ketamine administration enables a significantly less complex route of administration in the outpatient setting. Moreover, advances in insulin pump technology create the potential to monitor the brain wave activity and other physiologic parameters associated with ketamine administration and modulate ketamine therapy based on the patient's individual physiologic response."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRx Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL87341&sd=2024-04-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-development-of-new-proprietary-formulation-of-htx-100-iv-ketamine-302116345.html
SOURCE NRx Pharmaceuticals, Inc.
$AURI Auri, Inc. News! Auri Inc. Announces New Business Development
https://otcmarkets.com/stock/AURI/news/?id=436959
$GRLF
🌟 Big News: Green Leaf Innovations has filed the annual report & OTC removed the shell risk icon! We're in good standing & set for our strongest year in 2024. Onward & upward!
$GRLF
#Progress #Growth2024
🌟 Big News: Green Leaf Innovations has filed the annual report & OTC removed the shell risk icon! We're in good standing & set for our strongest year in 2024. Onward & upward! $GRLF#Progress #Growth2024
— Green Leaf Innovations, Inc. $GRLF (@otcgrlf) April 15, 2024
#BreakingNews: $PDGO Announces Acquisition of 100% Interest in 58 Oil and Gas Wells and 600 Acres of Land
in Oklahoma https://otcmarkets.com/stock/PDGO/news/PDGO-Announces-Acquisition?id=436678
Sergei Stetsenko, CEO of $BIDCF BlockchainK2, stated, "BlockchainK2 and RealBlocks are advancing the automation of financial markets through our innovative platform and are excited about leveraging Generative AI with Blockchain Tokenization for our clients and partners.
https://finance.yahoo.com/news/blockchaink2-announces-strategic-investment-realblocks-070000511.html
Beneficiary of conflict in Israel (NASDAQ: $SPCB) - Also revenue growth with earnings due out soon. New report lends insights into catalysts and earnings - https://seekingalpha.com/pr/19684306-bestgrowthstocks-com-issues-comprehensive-evaluation-of-supercom-ltd
$BIDCF 🇺🇸 🇨🇦 $BITK.V Keep On watch -- Hearing Big news coming soon..
BlockchainK2.com Announced on 2/20/24 Update on Strategic Investment in RealBlocks.com Blockchain Technology
#blovkchain #news #update
https://www.stockwatch.com/News/Item/Z-C!BITK-3513692/C/BITK
ECDA...................AKAN.................................https://stockcharts.com/h-sc/ui?s=ECDA&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=AKAN&p=D&yr=0&mn=2&dy=12&id=p84071410134
KULR................ICCM..................................https://stockcharts.com/h-sc/ui?s=KULR&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=ICCM&p=D&yr=0&mn=2&dy=12&id=p84071410134
Followers
|
1525
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
84736
|
Created
|
03/06/15
|
Type
|
Free
|
Moderator PennyMaster | |||
Assistants Golden Cross hstang04 Garyst BLULLISH |
*DISCLAIMER*
•The Board Moderator and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• Always do your own due diligence with any stock you may consider buying and never invest more than you are willing to lose.
• Stocks mentioned here may or may not be held by members posting on this board.
• There are no guarantees when buying or selling any security.
Posts Today
|
1
|
Posts (Total)
|
84736
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |